While at FDA, fellows will each be assigned a mentor who will be a senior member of FDA scientific review staff. Fellows will be matched with one of the mentors from the list below through a process of mutual selection. Mentors are listed in alphabetical order by last name.
Chief, Laboratory of Biological Chemistry (LBC), Division of Biotechnology Research and Review IV (DBRR IV), Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research
240-402-9387
Chemical synthesis of oligonucleotides for therapeutic and synthetic biology applications.
This project has important scientific and regulatory implications associated with the detection and treatment of infectious diseases and cancers. Indeed, antisense DNA oligonucleotides, aptamers, and small interfering RNA oligonucleotides (siRNA) have been used in vivo to treat various types of human diseases by altering the expression of disease-causing genes. Furthermore, our research objectives are aimed at minimizing process- and product-related impurities in synthetic nucleic acid sequences intended to be used as nucleic acid-based drugs. This can be achieved through the development of innovative solid supports and unique thermolabile groups for the protection of hydroxyl, amine and phosphate/thiophosphate functions of DNA and RNA sequences. Success in achieving those critical tasks will ensure the highest purity, safety and efficacy of nucleic acid-based drugs intended for pharmaceutical indications. Advances in creative technologies to enable highly efficient solid-phase chemical synthesis and purification of DNA and RNA sequences are essential to the project, particularly in the context of a continuous manufacturing process for nucleic acid-based drugs. First and foremost, the aims of this project are to fulfill the high demand for highly pure synthetic DNA and RNA sequences, which will be used in a variety of therapeutic and synthetic biology applications including chromosomal engineering.
As mentioned above, the key objectives of the project are to creatively design and implement the use of thermolabile groups to improve the automated solid-phase synthesis and purification of synthetic nucleic acid-based drugs with the intent of minimizing process- and product-related impurities to levels that will not be a safety concern to patients. Basic organic chemistry skills are required for this project given that modification of standard nucleic acid protecting groups are necessary to ensure the production of highly pure nucleic acid sequences. Skills in cell biology might alternatively be required should the IOTF fellow be considering working on the development of methods designed to enhance the cellular delivery of therapeutic DNA and/or RNA sequences as in vitro and in vivo inhibitors of protein-causing disease expression.
The review of incoming pre-Investigational New Drugs (pINDS) and Investigational New Drugs (INDS) submissions, and of the amendments of the currently active INDs, is the responsibility of the LBC. More than 400 active INDs are under review in the LBC; these INDs relate to a plethora of PEGylated and unPEGylated proteins including enzymes and antibodies. In addition, PEGylated and unPEGylated growth factors, erythropoetin-derived products, immunoconjugates, fibroblast and epidermal growth factors, thrombolytic and toxin-fusion proteins are among the active INDs under the jurisdiction of the LBC. The fellow will participate in the regulatory review of pIND and IND submissions. These activities will provide the fellow with a solid regulatory training under the tutelage of review teams dedicated to assessing the quality attributes of therapeutic proteins and enzymes, through a science-based approach.
Principal Investigator, Gene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration
240-402-6834
Assessing Immunogenicity of Products for Gene Therapy and T cell Therapy
Although T cell based cancer immunotherapy has shown a remarkable promise to treat various cancers, patients treated with therapeutic T cells can develop severe inflammatory disease notably cytokine release syndrome (CRS) in part due to activation of bystander immune cells. Furthermore, inflammation has become a critical risk factor in the clinical application of T cell immunotherapy. Immunosuppressive drugs that are used to manage the inflammation associated with T cell therapy also suppress the efficacy of therapeutic T cells. Thus, novel strategies to manage inflammation during T cell immunotherapy are required for their wide spread use against various cancers. The goal of this project is to develop strategies to reduce inflammation associated with T cell immunotherapy for cancer.
In this lab, fellow will utilize our established model to examine activation of therapeutic T cells in response to cancer antigens, and assess the intracellular signaling of cancer-specific T cells. Previous studies have shown that activated T cells secrete exosomes that induce bystander immune cell activation; however, the mechanism for this remains largely unknown. The IOTF fellow will study the role of exosomes secreted by CAR-T cells in bystander immune cell activation and inflammation associated with T cell immunotherapies. We expect that the knowledge gained from these studies will enhance our understanding of the role of exosomes in inflammation associated with T cell immunotherapy and aid to design safer and more effective cancer specific T cell therapies for future.
The IOTF fellow will participate in the regulatory review of investigational new drug (IND) applications for cell and gene therapy products. Many of these investigational new drug products are for the treatment of cancer. The fellow will also attend office and divisional regulatory meetings, and seminars. All of these activities will provide the fellow with a regulatory training to assess safety and efficacy of cell and gene therapy products.
Project Lead/Research-Review Chemist-CDER/OBP/DBRRII
ashwinkumar.bhirde@fda.hhs.gov
(240) 402-6234
Regulatory Science Priority Area: Evaluating cancer biotherapeutics (e.g., monoclonal antibodies, insulin analogs biosimilars) for stability under relevant stress conditions throughout the drug product life cycle
Running Project Title: Biosimilar Analytics: Biosimilar quality and impacts of container closure systems on particulates/particles
The Office of Biotechnology Products (OBP) in the Office of Pharmaceutical Quality (OPQ) evaluates the quality of biotherapeutic protein biosimilar and originator drug products (DPs). DP quality is impacted by variability in critical quality attributes, such as glycosylation patterns, high molecular weight species, and particles of injectable protein cancer biotherapeutics. The primary objective of this project is to evaluate biosimilar and reference products quality metrics in Insulin and other therapeutic protein drugs like monoclonal antibody DPs. Secondary objective of the project is to understand the impact of container closure systems and develop suitable methods to detect and evaluate particles in therapeutic protein formulations. The results of this project will be to disseminate the findings in peer-reviewed journals, internal/external forums (posters, talks) for stakeholders including drug and instrument manufacturers, and generate training materials for internal review staff. This project has multiple sub-projects and the IOTF can work on either of the project depending on the background and interest.
This project is divided into the following specific sub-projects:
Sub-project 1: OBP evaluates the quality of insulin DPs. OBP assessors and research labs have been working closely together as part of the OBP Insulin Working Group to address potential quality issues related to insulin DPs. Unlike other biotechnology DPs, insulin DPs are predominantly self-administered and potentially gets exposed to real-world stress conditions like agitation etc. This study aims to address regulatory review concerns regarding the stability of insulin biosimilars and originator DPs when using insulin in vials, pens, and pumps, to support insulin product manufacturing, testing and surveillance to ensure the delivery of high-quality insulin drugs. Potential real-world scenarios which may negatively impact insulin DPs including biosimilars quality will be evaluated.
Sub-project 2: Current reference standards to calibrate instruments for cancer therapeutic protein particle detection. However, these reference standards are physically rigid and vary in optical contrast when compared to protein particles which are soft, flexible, and irregular in shape and size. To address this short coming the National Institute of Standards and Technology (NIST) has developed novel proteinaceous particle surrogates as reference standards to help characterize particles in injectable cancer therapeutics. This project will evaluate the suitability of the NIST reference materials for particle detection in cancer drug formulations. In collaboration with NIST and the Office of Testing and Research at FDA, we propose to develop a novel morphologically-directed Raman spectroscopy method to characterize subvisible and visible particles using the NIST standards. The outcomes of this project will help update OBP recommended review practices for particulate matter testing requirements, help enhance the review process for drug applications, and provide support in the modernization efforts and improvements of US Pharmacopeia monographs for particles in protein DP injections.
The mentor is responsible for primary review of investigational new drug (IND’s) and supplemental biologic licensing applications (sBLA’s). He has in-depth experience in reviewing the chemistry manufacturing and controls of INDs and cross-reference INDs related to monoclonal antibodies etc., The mentor is also deeply involved in the development of regulatory policy including guidance documents, and OBP recommended practices. The IOTF fellow will be fully integrated into an existing team and will be provided with opportunities to participate in training and regulatory review activities related to regulatory submissions. The fellow will spend up to 50% of their time reviewing manufacturing, production, and quality of biotechnology product submissions related to the treatment of cancer and other indications. The fellow will also be exposed to regulatory policy and support working group activities from both a technical and regulatory perspective to gain expertise in the development of regulatory policy. The fellow will also attend lab, branch, divisional, and office level meetings, and may join the mentor at CDER or FDA level meetings to support regulatory or policy decision making, which is often germane to oncology drug products.
Research Physicist, Division of Imaging, Diagnostics, and Software Reliability, CDRH/OSEL
(301) 796-2663
Regulatory Science Priority Area: Develop methods and tools to improve and streamline clinical trial design
Assessment methodology development for medical image segmentation: from diagnostics to radiation therapy and imaging biomarkers for oncology trials
Artificial intelligence (AI) and machine learning (ML) algorithms are being developed at an ever-increasing pace for medical image segmentation, i.e., identifying the extent of lesions or an organ of interest, in diagnostic/therapeutic devices and imaging biomarker for drug trial applications with tremendous public health impact. Assessment of image segmentation is a key in clinical study endpoints that directly impact regulatory decisions for a broad spectrum of device and drug-trial applications, including image-guided radiation treatment planning, computer-assisted surgical devices, and imaging biomarkers as surrogate endpoints for drug trials. It is widely recognized that a standardized approach to the assessment of image segmentation is lacking [1-3]. Similarly, the agency lacks guidelines and the review of related submissions is challenging, slow and sometimes inconsistent.
In this project, a team of FDA scientists will develop assessment methodologies and tools to help industry as well as FDA reviewers decide on appropriate performance metrics and truthing methods for standardized assessment of image segmentation in diagnostic/treatment devices and drug trial applications. The project will help streamline and accelerate the regulatory review of related products. Depending on the skills and interests of the fellow, we will find a role to be filled in the project above. We are looking for help
* Managing a CT image dataset obtained from a collaborator * Develop or implement (i.e., based on open-source tools) image segmentation algorithms for radiation treatment planning * Work with the mentor and collaborators on the development of assessment methodologies including statistical modeling and analysis methods. * Training and provide technical support for regulatory review of premarket applications that involve AI for image segmentation, especially radiation treatment planning products.
AI based image segmentation for radiation treatment planning
premarket applications involving AI in radiation treatment planning, AI based imaging biomarkers
Principal Investigator, Genetic Toxicology Lab, OSEL, Division of Biology, Chemistry and Materials Science (DBCMS) CDRH
301-796-0237
Genetic Alterations, Cancer Risk, and Translational Diagnostics
Genetic alterations are implicated in the causation of cancer and recently cancer driver mutations (CDMs) have been used as biomarkers for diagnosis of cancer, stratification of patients into treatment groups, and monitors of therapy outcome. For safety assessment (cancer prevention), FDA assesses the capability for DNA interactions of new drugs, device materials, and food additives. In the area of cancer diagnosis and therapy, CDRH regulates genetic and genomic diagnostic devices, expected to be developed for the advent of "personalized medicine". In both aspects a central theme is the analytical capability for detection of rare mutant DNA within a background of normal DNA.
Exploration of “Comet-chip” for assessment of DNA damage. Comet-Chip is a new tool for monitoring mechanisms of genetic damage that can be used to study cytotoxicity, DNA repair, and DNA damage mechanisms. Relevant medical device applications, such as the actions of metals and nanoparticles will be addressed.
Diagnostics for early cancer detection and therapy monitoring. Detection of mutant DNA in blood and/or exosome RNA in urine or saliva would be the focus. K-RAS codon 12 mutations are a common biomarker for lung and pancreas cancers, and a good model for assessment of diagnostic tools, limits of detection, and human application. Exosomes are a new source of stable nucleic acid biomarkers and can be resourced from less invasive human compartments such as urine and saliva. Experiments would be designed for detection of spiked-in surrogate nucleic acids. Adequate systems development could be followed by an application for early diagnosis and therapy monitoring of pancreatic or lung cancer. This project would define the technical factors affecting detection of rare mutant DNA and/or RNA biomarkers.
Personalized cancer prevention: are we ready? It has been known for some time that both genes and environment are factors in human cancer development. In the era of precision medicine, what is the likelihood that we can begin to assess personalized cancer risk, instead of overall cancer risk? Cancers for which genetic, environmental, viral and other associations are well established include colon, liver, head and neck, and lung cancer. This project is a non-lab (or virtual) option for assembling epidemiological and other data on etiological factors affecting specific types of cancer, including those related to metals, radiation, or a rare type of breast implant associated lymphoma.
The PI has 20 plus years of FDA experience in the application of genetic analyses to cancer risk assessment of regulated products and is involved in the broader scientific community as past President of the US society of genetic toxicologists. The fellow would follow product reviews relative to cancer risk (device safety assessment) or cancer diagnostics (precision medicine), involving the CDRH Divisions that regulate Medical Devices or Diagnostic Tests respectively. The former group deals with the safety of 2000 categories of medical devices (cardiac, orthopedic, dental, hospital-based, etc.), while the latter group reviews diagnostic tests, including genetic and other tests used in precision-targeted cancer therapies. The fellow would focus on one or the other type of regulatory review.
Mathematician, Division of Imaging, Diagnostics, and Software Reliability (DIDSR), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), FDA
301-796-2531
Regulatory Science Priority Area: Unleashing the Power of Data, Increasing Choice and Competition Through Innovation, Women's Health - Advances in Biomarker Science
Digital Pathology
This objective of this project is to support the digital pathology revolution. Imaging devices, image processing tools, artificial intelligence algorithms, visualization packages, and display devices represent a large regulatory portfolio in CDRH that is continuing to expand. CDRH is in perpetual need of new paradigms for the evaluation of these products using reader studies, standardized databases, and modeling. These evaluations must be statistically interpretable, relevant for their intended use, and at reasonable cost. This project will investigate new, improved clinical trial designs and statistical methods, as well as develop and validate data collection and analysis tools, which will lead to more powerful clinical studies of the efficacy of imaging devices for fewer resources.
We are in the middle of a large multi-organization project in the area of digital pathology and artificial intelligence. Please refer to project publications that describe our work:
Depending on the skills and interests of the fellow, we will find a role to be filled in the project above. We are looking for help
Training courses will be offered to the Fellow on the premarket and post-market functions of CDRH, the importance of risk management in evaluating the safety of new medical products (like artificial intelligence and machine learning), how to conduct meetings, technical writing, and writing for sponsors. The Fellow will gain experience with the device approval process used in CDRH through exposure to actual submissions of imaging devices, computer-aided diagnostic (CAD) devices, and others. The fellow will assist in all aspects: the planning of trials, the review process, meeting with sponsors, writing letters to sponsors, and preparing/attending panel meetings.
Staff Scientist, Laboratory of Molecular Oncology, Division of Biotechnology Products Review and Research 1, Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), FDA
240-402-9634
Molecular mechanisms of epithelial neoplasia
The development of monoclonal antibodies for the targeted treatment of solid tumors is a major focus of efforts in the pharmaceutical arena as is evidenced by recent product approvals. An understanding of the molecular mechanisms underlying cancer pathogenesis is critical for the development and regulatory review of such therapies. In the Weinberg laboratory it is our aim to understand the molecular mechanisms involved in cancer pathogenesis by using the murine epidermis as a model system for the study of epithelial cancers. In particular the lab is focused on the p53 family, comprised of p53/p63/p73, which are expressed as multiple protein isoforms. These isoforms can mimic or interfere with one another, and their balance ultimately determines biological outcome in a context-dependent manner. Unlike p53 which is commonly mutated in human tumors, p63, and in particular the deltaNp63 subclass, is often overexpressed in human squamous cell cancers. However, normal levels of p63 expression are critical for normal epidermal development and homeostasis. The aim of the research is to understand the biological impact of dysregulated p63 expression and the molecular mechanisms of action underlying this impact using murine squamous epithelium in both in vitro and in vivo models.
Fellow will work on a project relating to the characterization of upstream interactions between the p63 and c-Rel pathways, mediation of downstream events, or targets impacted by the overexpression of deltaNp63 that are c-Rel dependent. This work will contribute to the overall research program of the Weinberg lab, which is focused on p63 and interacting pathways in epithelial biology and neoplasia. The fellow should have a good understanding of cancer, cellular and molecular biology. Candidates must have a Ph.D. and/or a M.D. and experience in cellular/molecular biology. The position will be located on the FDA White Oak Campus in Silver Spring, MD. Opportunities to participate in journal clubs and data sharing meetings exist.
Over nearly 30 years monoclonal antibodies have transformed from being solely a research tool to therapeutic agents for treating human disease. Today development of monoclonal antibodies is a major focus of pharmaceutical manufacturers. The Division of Monoclonal Antibodies is responsible for product quality review of antibodies, antibody conjugates, Ig-linked fusion proteins, ScFv, Fab’s and other antibody related proteins including those currently under development for the detection and treatment of solid tumors. The Fellow will be mentored to participate in regulatory responsibilities which may range from pre-IND meeting guidance to Sponsors through post-marketing manufacturing changes. The mentor has a strong interest in cell substrate characterization issues as they relate to biologics manufacturing and the use of emerging molecular methods for virus detection in biologics. Ample additional opportunities for reviewer training are available both at the divisional and office level.
Senior Staff Fellow, CBER/OTP/OCTHT/DCT1/CTTB
832-525-7188
Identification of manufacturing conditions that enhance cancer targeting capabilities of extracellular vesicles
Anticancer therapeutics can be administered systemically or locally to the diseased tissue to exert their effect; however, a number of challenges must be addressed to facilitate their clinical translation. In the case of widely investigated drug-loaded nanoparticles (NPs), only a small fraction of administered NPs reach the tumor site due to the inability to effectively cross biological barriers and reach the tumor cells directly. Additionally, these NPs can be phagocytosed or cleared by other cells (e.g. monocytes) thus reducing their anticancer effect and potentially requiring higher doses that could ultimately result in undesired harmful effects in terms of toxicity. Efforts to improve the targeting and permeability of NPs through conjugation of specific molecules/motifs has shown promise, but this approach is typically limited to single (or several) factor attachment, which may not be sufficient to ensure the NPs remain stable and efficiently reach the target tumor site. Therefore, identification of more complex, biologically-inspired surface recognition patterns and drug delivery systems could address this critical gap.
Our lab has developed a high throughput, morphological screening tool to assess the effects of different soluble cues on MSC production of extracellular vesicles. The IOTF will use this approach to screen novel 'priming' conditions (i.e. preconditioning) that alter the surface composition of EVs relevant to their ability to recognize cancer surface receptors and facilitate uptake of anticancer therapeutics. The fellow will then investigate how different manufacturing platforms (e.g. flasks vs. bioreactors) impact MSC-EV production and the subsequent cancer uptake/killing bioactivity. Together with other lab members we will associate the observed MSC-EV uptake/killing bioactivity with comprehensive proteomic and metabolomic profiles of the manufactured MSC-EVs. The knowledge gained through completion of this work will provide insight into the effect of manufacturing (soluble priming signals and scale) on MSC-EV bioactivity relevant to cancer treatment, as well as provide a generalizable platform for other EV-based therapeutics for diverse disease applications.
The IOTF fellow will work together with the mentor and participate in the regulatory review of investigational new drug (IND) applications for cell and gene therapy products for the treatment of cancer. Besides the direct mentorship, the fellow will have the opportunity to meet with and discuss other CMC-related challenges to development of cell and gene therapies through participation in consultations and regular lab branch meetings. The fellow will also be able to attend office and divisional regulatory meetings, and research/training seminars. Finally, there will be opportunities for educational outreach as the mentor has relationships with local universities that would greatly benefit from the regulatory science perspective provided by the IOTF fellow in any of the following formats: guest lectures, seminars, and in-person scientific demonstrations. Together, these regulatory activities, combined with the proposed regulatory science project, will provide the fellow with foundational regulatory training to assess safety and efficacy of cell and gene therapy products.
Deputy Director, Division of Radiological Health, Office of In Vitro Diagnostics and Radiological Health (OIR), Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA)
301-796-0294
Regulatory Requirements for Radiation Oncology (RO)
Like all medical treatments, radiation therapy treatments present both benefits and risk. Approximately 70% of all cancer patients will receive radiation therapy in one form or another. Of these patients, 60% will be treated with curative intent. This therapeutic modality has led to improvements in the treatment of numerous types of cancer. At the same time, it exposes patients to high doses of ionizing radiation (hereafter “radiation”), which elevates a person’s lifetime risk of developing cancer and can cause substantial morbidity. A balanced public health approach seeks to support the benefits of radiation therapy while minimizing the risk.
Patients should receive an optimal radiation dose, with the desired treatment effect on the tumor and sparing of normal tissue. FDA can advance this goal by using our regulatory authority judiciously while also collaborating with the healthcare profession community. FDA and our partners will take steps to:
By coordinating these efforts, we can optimize patient exposure to radiation, prevent treatment errors, and thereby reduce radiation-related risk while maximizing the benefits of RO treatment.
Conduct scientific reviews of radiation therapy devices to determine if changes in pre-market requirements or new post-market programs are necessary to maximize the benefits of radiation therapy with as low as reasonably achievable radiation doses. These reviews will include pre-market assessment of the regulatory data currently necessary to clear radiation therapy devices for clinical markets. The project will review post-market and compliance data from marketed radiation oncology devices to determine if the post-market and compliance issues with these devices can help predict the need for changes in regulatory scrutiny during pre-market evaluation. This project will provide input and direction for the implementation of FDA’s initiative to reduce exposure to radiation through dose reduction efforts related to equipment design and labeling. Regulatory activities related to radiation therapy treatments and regulatory changes for radiopharmaceuticals or chemotherapeutic drugs at FDA’s Center for Drug Evaluation and Research (CDER) will be assessed for impact on clearance of radiation therapy devices and our dose check program. This project will involve working with a team of interdisciplinary scientists to better regulate medical devices for radiation therapy. Also, the Fellow will provide input and direction in the implementation of FDA’s goal of reducing errors in radiation therapy through efforts related to training, equipment design and labeling, and education.
Expected 1 year accomplishments: Learn FDA’s pre-market, post-market and compliance review program for radiation therapy products. Assist in developing and guiding implementation of all aspects of FDA’s action plan for radiation therapy devices, as described above. Develop a monitoring plan and metrics to measure longer term outcomes of FDA’s action plan.
Chief, Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, CBER, FDA
240-402-7312
Evaluation of the safety of neoplastic cell substrates for viral vaccine production: Development of assays to assess tumorigenicity and oncogenicity
Vaccines have proven to be the best way to control infectious diseases. Vaccines are needed against such diseases as HIV/AIDS, pandemic influenza, MERS, Ebola virus, and Zika virus. Unfortunately, the current repertoire of cell substrates used to produce vaccines is inadequate and additional cells are needed. The types of cells required to manufacture these new vaccines are always immortal, some are tumorigenic, and some are derived from human tumors. The use of such cells presents regulatory hurdles such as the perceived risks of using cells that were derived from a human cancer to make preventative vaccines for infants and children. Our research attempts to address these concerns by establishing animal models capable of detecting the oncogenic activity of DNA. We have demonstrated that the animals most susceptible to the oncogenic activity of DNA are newborn rats and certain strains of newborn mice. Current work is centered on investigating whether the newborn p53-deficient mouse is as sensitive as other models and whether it has advantages over other rodents.
While specific projects change depending on progress being made, the general areas of research will be in evaluation of virus detection methodologies, understanding how cells become tumorigenic (which will involve investigating the contribution of epigenetics to tumorigenicity), and evaluating the oncogenicity of DNA in animal models.
Our area of regulation is in viral vaccines against diseases caused by HIV, influenza virus, Ebola virus, Zika virus, and other viruses; our specific areas of responsibility are in product safety and manufacturing as well as in evaluating vaccine effectiveness.
Chief, Laboratory of Applied Biochemistry, Division of Biotechnology Review and Research III, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research (CDER), FDA
240-402-7338
Protein oxidation and autophagy in the context of cancer chemotherapy and cardiotoxicity
Our goal is to understand the mechanisms of oxidative stress, protein oxidation and DNA damage in the context of drug quality, safety and efficacy, with an emphasis on cancer chemotherapy and cardiotoxicity. The anthracycline doxorubicin is a critical front-line treatment for primary breast cancer. Unfortunately, doxorubicin and other oncology agents also cause dose-limiting cardiotoxicity. The cardiac damage is thought to result from mitochondrial oxidative stress that causes free radical damage to heart muscle. Previous combination therapies aimed at cardioprotection have used non-specific antioxidants that have failed to show clinical benefit. How autophagy plays a role in such drug resistance is also unclear. We have identified specific proteins that are oxidized under cardiotoxic conditions that could serve as biomarkers of adverse events and targets for cardioprotective drug development. We validated a syngeneic, preclinical animal model for investigating the safety signals from a range of small molecule and biotechnology-derived oncology agents. We apply Next Generation Sequencing technologies to decipher genetic links to the regulation of oxidative stress. Using cellular, animal models and patient-derived samples, we aim to characterize the molecular and genetic pathways by which oxidants and anti-oxidants effect cardiac and tumor biology. Towards this overall goal we have three ongoing, oncology-related projects: (1) elucidate the mechanisms of cell death and autophagy by mitochondrially-targeted redox agents, (2) the application of a syngeneic animal model for studying cardiotoxicity and antitumor efficacy of small molecule and biotechnology derived drugs, and (3) apply Next-Generation Sequencing technology to identify genomic signatures linked to drug-related adverse events.
The fellow will have the opportunity to pursue one of several research projects based on his/her interest within the context of cancer chemotherapy. Candidates must have a good understanding of cancer biology, biochemistry and molecular biology. Position is located on the main campus of the FDA at White Oak in Silver Spring, MD. The fellow will also have opportunities to interact and collaborate with oncologists and NCI laboratories on specific joint projects. The Fellow will also be expected to participate in regular research meetings and seminars.
The Office of Biotechnology Products regulates a broad range of therapeutic agents such as monoclonal antibodies and cytokines including, but not limited to, oncology products. The fellow will actively participate in the team-based review of investigational new drug applications. The fellow will be expected to attend regulatory training sessions and participate in regulatory meetings.
Related References:
Principal Investigator, Laboratory of Cellular Hematology, Division of Blood Components and Devices (DBCD), Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA
Tel: 240-402-7393
Investigation of Potential Toxic Effects of Extracellular Membrane Vesicles in Blood and Blood Products and their Biomarker Applications
Our research program is focused on application and development of high resolution nanoscience analytical and imaging methods for analysis of membrane micro- and nanovesicles in blood and blood products. Cell membrane extracellular vesicles (EVs), also called membrane microparticles, are phospholipid vesicles, 40 nm 1000 nm in size, released in blood from membranes of blood cells, platelets, endothelial cells, and other cell types. Different populations EVs are present in the circulating blood of healthy donors; rises in the levels of EVs in the blood are associated with various diseases, including cancer, and may serve as biomarkers. EVs are released from blood cells during processing and storage of cellular blood components, the potential for EVs to cause adverse events following the administration of blood products is also a concern. In addition, in frozen and freeze dried platelet derived hemostatic products, submicron EVs represent a major component with a marked impact on the product in vitro procoagulant potency and potentially also on safety and efficacy in vivo.
The project will focus on development of analytical assays for detection, characterization, and immunophenotyping of EVs in blood. More than 90% of EVs present in blood and blood products are smaller than 300 nm, most are of exosome size 40 -100 nm. These nanoscale EVs are not detectable by traditional analytical methods, such as conventional flow cytometry. Thus, there is an urgent need for novel reliable methods for analysis of membrane micro- and nanovesicles in blood and blood products.
Laboratory of Cellular Hematology regulates cellular transfusion products, including red blood cells, platelets, and platelet substitutes. We also regulate devices and solutions used for collection, processing, storage, and pathogen reduction of these products. In addition, bacterial detection assays and leukocyte counting assays for blood product testing are regulated in our laboratory.
Principal Investigator, Division of Biotechnology Research and Review 1 (DBRR1), Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research
240-402-7407
Modulation of renal cell carcinoma metabolism by immune checkpoint inhibitors.
With about 120,000 deaths worldwide each year, kidney cancer is one of the most lethal urologic cancers. Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumors, representing 75% of cases. Patients with advanced stages of ccRCC have a 5-year survival rate of only 11.7%, underscoring the need to improve the efficacy and safety of current therapies. Advanced ccRCC present a metabolic shift toward aerobic glycolysis (TCGA, Nature 2013), consistent with the idea that metabolic flexibility is important for their survival. Therapeutic pressure could be a driver of metabolic flexibility, thus, understanding how current therapies affect ccRCC metabolism will allow for better development of biomarkers of efficacy or resistance. There are currently 95 active/recruiting clinical trials for ccRCC: 42 (44%) involve biologics, 61% of which (27) comprise immune checkpoint inhibitors (ICIs). Recent reports demonstrated the modulation of tumor metabolism by ICIs (Chang et al, Cell 2015), however little is known about ICIs’effects on ccRCC. Thus, identifying the metabolic events associated with ccRCC’s response or resistance to therapies involving ICIs is an important step toward the development of non-invasive biomarkers to improve the safety and efficacy of therapies.
Based on his/her experience and interest, the fellow will have the opportunity to select one or more projects derived from the research program previously described with the goal to understand how ICIs affect tumor metabolism and/or their micro-environment, and how this relates to efficacy and resistance to therapy.
As a team member of OBP/Division 1, the fellow will gain experience in diverse aspects of the regulatory review of therapeutic monoclonal antibodies to assess their efficacy and safety. The fellow will have access to formal regulatory trainings and will participate in the office and division regulatory activities.
Principal Investigator, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research (CBER), FDA
240-402-7994
Assess the role of tumor microenvironment in cancer therapy
The tumor microenvironment is an essential and necessary partner in the progression of cancer to more aggressive stages. Various stromal components in the tumor microenvironment such as fibroblasts, endothelial cells, and inflammatory cells respond via several signaling mechanisms to further drive the aggressive progression of cancer cells and affect responses to therapeutic products. Accordingly, understanding crosstalk between therapeutic products and the tumor microenvironment is essential to achieve desired clinical outcomes of the therapeutic products. This project will assess the role of the tumor microenvironment on the efficacy of therapeutic products targeting breast cancer (e.g., CAR T cells) using a microscale, 3D in vitro breast cancer model. Microscale, 3D in vitro models provide unique functionality and are emerging as useful tools to examine complex interactions between tumor cells and stromal fibroblasts by providing enhanced spatial and temporal controls over microenvironmental cues. The outcome of this project will provide better understanding in advancing the safety and efficacy of therapeutic products for treating breast cancer by identifying mechanisms of the tumor microenvironment that limit the success of these therapies in clinical trials.
CAR T cell therapies have shown limited efficacy in treating solid tumors due to barriers in the tumor microenvironment, such as the extracellular matrix (ECM) and stromal cancer associated fibroblasts (CAFs), which limit T-cell infiltration in solid tumors and promote immunosuppression. These microenvironmental barriers against T-cell infiltration and CAF-mediated immunosuppression, while difficult to study in complex in vivo models, can be studied independently using in vitro tumor models that provide control over microenvironmental cues. The fellow will study the roles of the ECM and CAFs on the safety and efficacy of CAR T cells designed to react against breast cancer (e.g., anti-HER2 CAR T cells against HER2+ breast cancer). The fellow will develop a microscale, 3D model of the breast cancer microenvironment that recapitulates these barriers and enables the study of CAR T cell migration towards, and cytotoxicity against, breast tumor cells. The results of this project will provide mechanistic insights into potential therapies that can improve the efficacy of CAR T cell therapy in breast cancer.
Dr. Sung is a product reviewer and is experienced in the regulatory review of investigational new drug (IND) applications for cell therapy products as well as device submissions (e.g., 510(k) premarket notifications and investigational device exemptions (IDE)). Many of these are for the treatment of cancer. Under the mentorship of Dr. Sung, the IOTF fellow will participate in the regulatory review of INDs and device submissions. The fellow will also attend regulatory meetings including office and division regulatory meetings.
Senior Investigator and Chief, Laboratory of Molecular Oncology, Division of Biotechnology Review and Research 1, Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), FDA
240-402-7472
Molecular Mechanisms Involved in Regulating Epithelial Differentiation, Neoplasia and Therapeutic Efficacy
Despite major advances in identifying rational targets and early promising pre-clinical findings, the majority of cancer treatments proceeding through clinical trials fail. To maximize the predictive value of pre-clinical data, the models utilized must reflect as much as possible the disease etiology. Our laboratory has established novel preclinical models that reflect the altered gene expression profiles seen in human squamous cancers, and correlate a variety of in vitro assay endpoints with in vivo phenotype to aid in defining optimal bioassays for product development and characterization. Current work focuses on elucidating the biological impact and mechanism of action of p63 gene dysregulation, as has been described in human squamous cell cancers of the head and neck (HNSCC), lung, breast, cervix and ovaries. The overall goal of our research is to identify biomarkers of tumor progression and responsiveness for cancer diagnosis, monitoring therapeutic efficacy and assessing critical product quality attributes.
A research position is available to evaluate the impact of p63 gene dysregulation, as seen in human cancers, on normal keratinocyte growth regulation, differentiation and neoplasia, and defining interacting pathways in multistep carcinogenesis. The project will utilize a variety of cellular and molecular biology methodologies, in vivo and in vitro approaches, human cancer cell lines, and novel knockout and transgenic mice to clarify the molecular pathways contributing to epithelial cell transformation, and the role of p63 in the response to cancer therapeutics. Ongoing studies address the interaction of dysregulated p63 levels with the NFkB and ras pathways, modulating cancer initiating cell populations and tumor progression, defining the tumor microenvironment in an in vivo model of HNSCC for therapeutic strategies, and bioassay development for drug repurposing. The particular project to be undertaken will reflect the specific interests of the fellow. Candidates must have a Ph.D. and/or M.D. and experience in cell/molecular biology. The position is located on FDA’s White Oak campus in Silver Spring, MD.
The development of antibody-based therapies comprises one of the most active areas of clinical research in oncology today. Many targeted therapies based on our current molecular understanding of cancer pathogenesis are under development to optimize the treatment outcome of tumors with specific genetic alterations. The Laboratory of Molecular Oncology is responsible for product review of biotechnology products, primarily monoclonal antibodies (Mab) and Mab-based products such as antibody-drug conjugates, Ig-linked fusion proteins, ScFv, and Fab’s, including those currently under development for detection and treatment of solid cancers. The fellow will be mentored to participate in regulatory responsibilities which may range from pre-IND guidance through review of licensing applications and post-marketing manufacturing changes.
Senior Investigator, Division of Biotechnology Research and Review 1 (DBRR1), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), FDA
240-402-6715
HER2 signaling and HER2-targeted antibody therapeutics
Three areas of research are currently being pursued in Dr. Wu’s laboratory at FDA. The first involves studies of HER2 signaling in breast cancer progression and HER2 targeted antibody therapeutics, including antibody-drug conjugates (ADC) and bispecific antibodies, with emphasis on therapeutic resistance and toxicity induced by trastuzumab and ado-trastuzumab emtansine (T-DM1). The second area of research focuses on antibody engineering. We generate and characterize bi-specific antibodies for the treatment of breast cancers. The third is to investigate the safety and efficacy of immune checkpoint inhibitors for the treatment of breast cancers. These research projects address product quality issues, mechanisms of actions/drug resistance, and adverse events associated with FDA-regulated products.
The fellow will carry out research projects concerning important current issues related to the therapeutic resistance of monoclonal antibodies and toxicity, e.g. hepatotoxicity and cardiotoxicity, induced by FDA-approved HER2-targeted antibody therapeutics. The fellow will participate in research activity related to antibody engineering and design, express, and characterize bispecific antibodies. The IOTF fellow may have the opportunity to work on a different research project that is currently conducted in our laboratory depending on fellow’s background and interest.
The DBRR1 is responsible for the product quality review of monoclonal antibodies and monoclonal antibody-derived products, including antibody conjugates, bi-specific antibodies, and other antibody related proteins. Our laboratory is involved in regulating novel monoclonal antibodies, including antibody-drug conjugates and bispecific antibodies, for the treatment of human cancers. The fellow will participate in regulatory review of investigational new drug (IND) applications. This provides the opportunity for the fellow to work as part of regulatory team to assess the product quality of therapeutic monoclonal antibodies and participate in meetings with the sponsors.
Senior Staff Fellow, Gene Transfer and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA
240-402-7471
Efficacy and safety evaluation of stem cell engineering technologies
Human stem cells have great potential in both regenerative medicine and cancer immunotherapies. However, significant roadblocks exist due to inefficient differentiation of stem cells to specialized lineages such as functional T cells. We study the developmental processes required for blood cell generation and lymphocyte specification from induced pluripotent stem cells (iPSCs) using tissue culture and animal transplantation models. Advanced genetic engineering technologies are used to modulate differentiation and to enhance anti-tumor activity of the differentiated cells. A second area in our research concerns the safety of gene therapy approaches, some of which have been linked to leukemia development in clinical trials. Of particular interest are safety of advanced genome editing technologies. We develop in vitro methods and xenotransplantation models to study the efficiency and specificity of genome editing tools on their effect on genomic instability and tumor initiation.
The IOTF fellow’s research can focus on one of two areas: 1) Developing cancer immunotherapy strategies using human iPSCs. This project will examine methods for generating off-the-shelf adoptive immunotherapy with enhanced safety features and more defined CAR expression levels than conventional viral vector transduced primary lymphocytes. 2) Establishing methods for evaluating emerging genome editing tools and their safety in gene therapy product development. This project will focus on improving efficiency of these technologies in human stem cells and understanding the biochemical mechanisms underlying unintended targeting events.
Dr. Ye’s main regulatory activity is chemistry, manufacturing and controls review of gene therapy products. In addition, he provides consultation to pharmacology/toxicology reviewers on issues related to pluripotent stem cells and genome editing technologies. Under Dr. Ye’s mentorship, the IOTF fellow is expected to gain regulatory experience by participating in the review of investigational new drug (IND) applications of gene and cell therapy products and by participating in relevant regulatory working group activities.
SBRBPAS Expert, Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research, Food and Drug Administration
240-402-6740
Regulatory Science Priority Area: Improve product manufacturing, testing, and surveillance to help ensure the availability of high-quality drugs
Bioassays for biotechnology products
Bioassays or potency assays are a critical component of quality control strategies for biotechnology products, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). Dr. Zhang’s laboratory has a track record of research and regulatory expertise in the development of bioassays for biotechnology products and other complex drug products. Currently, the Lab is working to develop functional bioassays for therapeutic antibodies indicated for treatment of cancer and COVID-19. The bioassay research aligns with the Agency’s regulatory mission to ensure product quality and manufacturing consistency, thus facilitating evaluation or development of FDA-regulated products and supports regulatory decision-making and policy development.
The Fellow will join in a multidisciplinary research team to develop and validate novel bioassays for therapeutic antibodies (mAbs, BsAbs, ADCs). This includes assessing the functional impacts of variability in critical product quality attributes (CQAs) - especially those resulting from glycosylation and aggregation of antibody products regulated by FDA.
The Office of Biotechnology Products (OBP) regulates a broad array of biotechnology products (e.g., recombinant proteins, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, biosimilars, combination products). The Fellow will actively participate in the team-based review of INDs and BLAs and their respective amendments and supplements.